Purpose of review Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) disorder in the population and it carries a poor visual prognosis. In this article, we review the development of treatment strategies for LHON, the evidence base and the areas of unmet clinical need.
INTRODUCTION
LHON (OMIM 535000) is the most common primary mitochondrial DNA (mtDNA) disorder with a prevalence of 1 in 31 000-50 000 in Northern European populations and an estimated incidence of 1 in 1 000 000 in the Japanese population [1] [2] [3] . Three point mutations within the mitochondrial genome, m.3460G>A (MTND1) m.11778G>A (MTND4), and m.14484T > C (MTND6), account for about 90% of all LHON cases. These mtDNA mutations disrupt critical complex I subunits of the mitochondrial respiratory chain, causing impaired cellular ATP synthesis and increased production of reactive oxygen species (ROS) [2, 4] . The remaining 10% of LHON cases harbour rarer pathogenic mtDNA mutations, which individually have been reported in only a limited number of patients worldwide [4] [5] [6] . Furthermore, there is a subset of patients with a LHON-like presentation who are not found to harbour any clear pathogenic variants on whole mtDNA sequencing. Some of these cases could be caused by a combination of multiple mtDNA variants that synergistically trigger retinal ganglion cell (RGC) loss or deleterious variants in nuclear-encoded genes, such as NDUFS2 [6,7 && ,8].
Although the peak age of onset is between 15 and 35 years, patients with LHON have been reported from 2 to 87 years of age [5, 9] . LHON typically presents with unilateral, painless, subacute, central visual loss with the fellow eye becoming involved within the following 6 months [10 & ]. In about 25% of cases, there is simultaneous involvement of both optic nerves at first presentation [2, 11] . An international consensus statement has defined three clinical stages in LHON based on the time from onset of visual loss, namely, subacute Idebenone is a synthetic, short-chain analogue of ubiquinone, which is responsible for shuttling electrons from complexes I and II directly to complex III [13] . Idebenone has greater bioavailability compared with coenzyme Q10 (CoQ10) as it possesses a less lipophilic tail that allows it to penetrate the blood-brain barrier and mitochondrial membrane more readily [14] . The efficacy of idebenone was assessed in a randomized, double-blinded, placebo-controlled study (RHODOS), which recruited 82 patients with LHON harbouring one of the three common mtDNA mutations (Table 1) . Patients were randomized in a 2:1 ratio in favour of idebenone and a dose of 300 mg three times a day was used over a treatment period of 24 weeks [15, 16] . In addition to RHODOS, the visual benefit of idebenone was assessed as part of a retrospective review of 103 patients treated with idebenone at varying doses and treatment duration [17] . Both these studies support a visual benefit in a proportion of patients treated with idebenone and the likelihood of a positive response was increased with earlier initiation of treatment. This is in keeping with the hypothesis that in the acute stage of LHON, a proportion of RGCs are functionally suppressed, but have not yet committed irreversibly cell death, and this pool of RGCs can be rescued if treatment is provided within a critical time window. Idebenone has been approved by the European Medicine Agency (EMA) to treat LHON and postmarketing studies are currently underway to collect additional safety and efficacy data [13] .
Other neuroprotective agents
Two neuroprotective drugs, EPI-743 and MTP-131 (elamipretide), have been used for patients with mitochondrial disease [18, 19] . In an open-labelled study, preliminary data of efficacy for EPI-743 was demonstrated in five patients with subacute LHON [19] . 
Improving mitochondrial biogenesis
LHON is a complex disease and the phenotypic manifestation of the primary mtDNA mutation is influenced by secondary genetic factors, environmental triggers and hormonal influences [24, 25] . The mitochondrial genome is a high copy number genome and the factors that control a cell's overall copy number are thought to be relevant to both physiological and pathological states [26] . Interestingly, unaffected LHON mutation carriers and normal healthy controls have a higher mtDNA copy
KEY POINTS
Leber hereditary optic neuropathy (LHON) is characterized by the preferential loss of retinal ganglion cells within the papillomacular bundle resulting in a dense central scotoma.
Agents that increase mitochondrial biogenesis have shown promise in mitigating the deleterious effects of the LHON mitochondrial DNA (mtDNA) mutations in the cell models studied.
Gene therapy based on allotopic expression of wildtype MTND4 is currently being investigated for patients carrying the m.11778G>A mtDNA mutation.
Mitochondrial replacement therapy has been developed to prevent the maternal transmission of pathogenic mtDNA mutations. [27] . These observations could also explain the marked sex bias in LHON with the preponderance for male carriers losing vision being due, at least partly, to lower circulating levels of oestrogens [27,28 && ,29] . Smoking is a major risk factor for visual loss in LHON and in keeping with this detrimental effect, LHON fibroblasts cultured in the presence of cigarette smoke condensates exhibit significantly decreased mtDNA copy number [30, 31] . However, further experimental work is required to refine and test specific therapeutic agents that target mitochondrial biogenesis before moving into early-phase clinical trials [32] .
Near-infrared light therapy
Photobiomodulation with near-infrared light-emitting diode arrays increases the production of cytochrome c oxidase in cultured primary neurons and it reverses the reduction in enzymatic activity caused by metabolic inhibitors [33] . Recent experimental data in axotomy models of neurodegeneration look promising, but the translational application of this therapeutic paradigm to optic neuropathies poses a number of technical and practical challenges that will need to be overcome [34] . A previous study failed to recruit a sufficient number of patients to explore whether near-infrared light therapy could influence the visual prognosis in LHON (https:// clinicaltrials.gov/ct2/show/NCT01389817, accessed 1 st November 2018).
MITOPHAGY MODULATION
Mitophagy refers to the selective autophagocytosis of mitochondria and this tightly regulated process allows the elimination of damaged mitochondria that would otherwise compromise the cell's survival. The balance between mitochondrial biogenesis and degradation has been investigated in LHON cybrid models and the available data indicates that mitophagy is dysregulated with impaired mitochondrial function and cell survival [35,36 & ]. Based on these findings, activation of mitophagy by pharmacological means is being explored as a potential therapeutic strategy for mitochondrial diseases.
GENE THERAPY
The eye represents an ideal target organ for gene therapy given the relative ease of access for direct delivery of viral vectors [37] . A major challenge in the treatment of mitochondrial disease is the double-membrane nature of the mitochondrial compartment, which complicates the efficient import of exogenous proteins. To bypass this physical barrier, an alternative strategy is to express the replacement wild-type gene in the nuclear compartment and the resulting protein is designed to contain a mitochondrial targeting sequence, which directs for its importation into mitochondria [38] . Following the successful demonstration that allotopic expression of wild-type MTND4 could rescue the phenotype both in cell and animal models of LHON, human clinical trials have been initiated using modified adeno-associated virus vectors to deliver the gene construct [39] [40] [41] 42 && ]. These groundbreaking studies have shown the safety of this approach and the preliminary results obtained are encouraging indicating the preservation of RGCs and a functional visual benefit in a proportion of treated eyes.
Mitochondrial replacement therapy
As the mitochondrial genome shows strict maternal inheritance, preventing the transmission of pathogenic mtDNA mutations from mother to child is a major area of research for a number of research groups worldwide. Two main in-vitro fertilization (IVF) techniques have been developed, namely, pronuclear transfer and maternal spindle transfer, both of which require the contribution of a donor egg that carries only wild-type mtDNA [43] . The term 'three-parent embryo' is frequently used in the lay press as the mitochondrial genome of the resulting embryo is derived from the donor egg, whereas the nuclear genome is inherited from the biological parents. In 2015, mitochondrial replacement therapy was approved by both Houses of Parliament in the United Kingdom as a justifiable reproductive option with the caveat that it should only be carried out in a recognized centre of excellence and with long-term follow-up of the children born using this approach [44] . In contrast, the US Food and Drug Administration has concluded that more experimental and safety data are needed before advocating mitochondrial replacement therapy as reproductive option for mitochondrial disease [32, 44] . As the legal and ethical implications of mitochondrial donation was being openly debated, the media reported that maternal spindle transfer had resulted in the birth of a healthy baby boy who carried low levels of the m.8993T > G mtDNA mutation in MTAP6 that had resulted in the premature death of two siblings from Leigh syndrome [45 & ]. Mitochondrial replacement therapy remains controversial and both the regulatory framework and the consequences of modifying the germ line need to be carefully considered [44] . Regenerative Medicine
The seminal discovery that somatic cells could be reprogrammed into pluripotent stem cells, so called induced pluripotent stem cells (iPSCs), has transformed the scope for regenerative medicine, in particular for progressive neurodegenerative diseases [46] . Although the generation of iPSCs carrying pathogenic mtDNA LHON mutations is now technically straightforward, their differentiation into RGCs and the generation of a homogenous population in sufficient quantity for experimental needs still remain challenging [47 & ]. Other hurdles that will need to be overcome before considering the use of iPSC-derived RGCs in LHON and other optic neuropathies are the methods required to deliver the cells in a viable state to the right retinal location and providing the guiding signals needed to allow the axonal projections of the transplanted cells to make the correct retinotopic connections [48] [49] [50] .
CONCLUSION
LHON is a rapidly progressive, blinding disorder that typically affects young adults in their prime. The management of LHON remains largely supportive, but rapid advances in drug discovery, gene therapy and stem cell technology are providing researchers with new tools for rescuing RGCs in this disorder with the aim of stabilizing vision and improving the visual outcome. Central to these endeavours is the need to ensure patient safety both in early phase experimental trials and as part of long-term followup studies.
